These findings not only advance our understanding about the functional operation of the striatal circuitry, but also have therapeutic implications for PD, that is, agents with mixed D1R and D2R agonistic properties are better than pure D1R or D2R agonists. The gene discussed is DRD1; the disease is Parkinson disease.